<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.jnrbm.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Negative Results in BioMedicine - Latest Articles</title>
        <link>http://www.jnrbm.com</link>
        <description>The latest research articles published by Journal of Negative Results in BioMedicine</description>
        <dc:date>2010-06-23T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/5" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/4" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/3" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/2" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/9/1/1" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/12" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/11" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/10" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/9" />
                                <rdf:li rdf:resource="http://www.jnrbm.com/content/8/1/8" />
                            </rdf:Seq>
        </items>
        <extra:info rdf:parseType="Literal">
            <html:div style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif" xmlns:html="http://www.w3.org/1999/xhtml">
                <html:span style="font-weight:bold">
                    This is an RSS newsfeed from BioMed Central
                </html:span>
                <html:br />
                <html:span style="font-size: 12px;">
                    It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit
                    <html:br />
                    <html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">
                        http://www.biomedcentral.com/info/about/rss/
                    </html:a>
                    <html:br />
                </html:span>
            </html:div>
        </extra:info>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.jnrbm.com/content/9/1/5">
        <title>The Drosophila Anion Exchanger (DAE) lacks a detectable interaction with the spectrin cytoskeleton</title>
        <description>Background:
Current models suggest that the spectrin cytoskeleton stabilizes interacting ion transport proteins at the plasma membrane. The human erythrocyte anion exchanger (AE1) was the first membrane transport protein found to be associated with the spectrin cytoskeleton. Here we evaluated a conserved anion exchanger from Drosophila (DAE) as a marker for studies of the downstream effects of spectrin cytoskeleton mutations.
Results:
Sequence comparisons established that DAE belongs to the SLC4A1-3 subfamily of anion exchangers that includes human AE1. Striking sequence conservation was observed in the C-terminal membrane transport domain and parts of the N-terminal cytoplasmic domain, but not in the proposed ankyrin-binding site. Using an antibody raised against DAE and a recombinant transgene expressed in Drosophila S2 cells DAE was shown to be a 136 kd plasma membrane protein. A major site of expression was found in the stomach acid-secreting region of the larval midgut. DAE codistributed with an infolded subcompartment of the basal plasma membrane of interstitial cells. However, spectrin did not codistribute with DAE at this site or in anterior midgut cells that abundantly expressed both spectrin and DAE. Ubiquitous knockdown of DAE with dsRNA eliminated antibody staining and was lethal, indicating that DAE is an essential gene product in Drosophila.
Conclusions:
Based on the lack of colocalization and the lack of sequence conservation at the ankyrin-binding site, it appears that the well-characterized interaction between AE1 and the spectrin cytoskeleton in erythrocytes is not conserved in Drosophila. The results establish a pattern in which most of the known interactions between the spectrin cytoskeleton and the plasma membrane in mammals do not appear to be conserved in Drosophila.</description>
        <link>http://www.jnrbm.com/content/9/1/5</link>
                <dc:creator>Ronald Dubreuil</dc:creator>
                <dc:creator>Amlan Das</dc:creator>
                <dc:creator>Christine Base</dc:creator>
                <dc:creator>G Mazock</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, 9:5</dc:source>
        <dc:date>2010-06-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-5</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2010-06-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/9/1/4">
        <title>Lack of effects of typical and atypical antipsychotics in DARPP-32 and NCS-1 levels in PC12 cells overexpressing NCS-1</title>
        <description>Background:
Schizophrenia is the major psychiatry disorder, which the exact cause remains unknown. However, it is well known that dopamine-mediated neurotransmission imbalance is associated with this pathology and the main target of antipsychotics is the dopamine receptor D2. Recently, it was described alteration in levels of two dopamine signaling related proteins in schizophrenic prefrontal cortex (PFC): Neuronal Calcium Sensor-1 (NCS-1) and DARPP-32. NCS-1, which is upregulated in PFC of schizophrenics, inhibits D2 internalization. DARPP-32, which is decreased in PFC of schizophrenics, is a key downstream effector in transducing dopamine signaling. We previously demonstrated that antipsychotics do not change levels of both proteins in rat&apos;s brain. However, since NCS-1 and DARPP-32 levels are not altered in wild type rats, we treated wild type PC12 cells (PC12 WT) and PC12 cells stably overexpressing NCS-1 (PC12 Clone) with antipsychotics to investigate if NCS-1 upregulation modulates DARPP-32 expression in response to antipsychotics treatment.
Results:
We chronically treated both PC12 WT and PC12 Clone cells with typical (Haloperidol) or atypical (Clozapine and Risperidone) antipsychotics for 14 days. Using western blot technique we observed that there is no change in NCS-1 and DARPP-32 protein levels in both PC12 WT and PC12 Clone cells after typical and atypical antipsychotic treatments.
Conclusions:
Because we observed no alteration in NCS-1 and DARPP-32 levels in both PC12 WT and Clone cells treated with typical or atypical antipsychotics, we suggest that the alteration in levels of both proteins in schizophrenic&apos;s PFC is related to psychopathology but not with antipsychotic treatment.</description>
        <link>http://www.jnrbm.com/content/9/1/4</link>
                <dc:creator>Bruno Souza</dc:creator>
                <dc:creator>Karen Torres</dc:creator>
                <dc:creator>Debora Miranda</dc:creator>
                <dc:creator>Bernardo Motta</dc:creator>
                <dc:creator>Estevao Scotti-Muzzi</dc:creator>
                <dc:creator>Melissa Guimaraes</dc:creator>
                <dc:creator>Daniel Carneiro</dc:creator>
                <dc:creator>Daniela Rosa</dc:creator>
                <dc:creator>Renan Souza</dc:creator>
                <dc:creator>Helton Reis</dc:creator>
                <dc:creator>Andreas Jeromin</dc:creator>
                <dc:creator>Marco Romano-Silva</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, 9:4</dc:source>
        <dc:date>2010-06-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-4</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2010-06-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/9/1/3">
        <title>Effect of venlafaxine on bone loss associated with ligature-induced periodontitis in Wistar rats</title>
        <description>Background:
The present study investigated the effects of venlafaxine, an antidepressant drug with immunoregulatory properties on the inflammatory response and bone loss associated with experimental periodontal disease (EPD).Materials and MethodsWistar rats were subjected to a ligature placement around the second upper left molar. The treated groups received orally venlafaxine (10 or 50 mg/kg) one hour before the experimental periodontal disease induction and daily for 10 days. Vehicle-treated experimental periodontal disease and a sham-operated (SO) controls were included. Bone loss was analyzed morphometrically and histopathological analysis was based on cell influx, alveolar bone, and cementum integrity. Lipid peroxidation quantification and immunohistochemistry to TNF-&#945; and iNOS were performed.
Results:
Experimental periodontal disease rats showed an intense bone loss compared to SO ones (SO = 1.61 &#177; 1.36; EPD = 4.47 &#177; 1.98 mm, p &lt; 0.001) and evidenced increased cellular infiltration and immunoreactivity for TNF-&#945; and iNOS. Venlafaxine treatment while at low dose (10 mg/kg) afforded no significant protection against bone loss (3.25 &#177; 1.26 mm), a high dose (50 mg/kg) caused significantly enhanced bone loss (6.81 &#177; 3.31 mm, p &lt; 0.05). Venlafaxine effectively decreased the lipid peroxidation but showed no significant change in TNF-&#945; or iNOS immunoreactivity.
Conclusion:
The increased bone loss associated with high dose venlafaxine may possibly be a result of synaptic inhibition of serotonin uptake.</description>
        <link>http://www.jnrbm.com/content/9/1/3</link>
                <dc:creator>Rosimary Carvalho</dc:creator>
                <dc:creator>Carolina de Souza</dc:creator>
                <dc:creator>Julliana Neves</dc:creator>
                <dc:creator>Sergio Holanda-Pinto</dc:creator>
                <dc:creator>Livia Pinto</dc:creator>
                <dc:creator>Gerly Brito</dc:creator>
                <dc:creator>Geanne de Andrade</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, 9:3</dc:source>
        <dc:date>2010-06-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-3</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2010-06-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/9/1/2">
        <title>Human haematopoietic stem cells express Oct4 pseudogenes and lack the ability to initiate Oct4 promoter-driven gene expression </title>
        <description>The transcription factor Oct4 is well defined as a key regulator of embryonic stem (ES) cell pluripotency. In recent years, the role of Oct4 has purportedly extended to the self renewal and maintenance of multipotency in adult stem cell (ASC) populations. This profile has arisen mainly from reports utilising reverse transcription-polymerase chain reaction (RT-PCR) based methodologies and has since come under scrutiny following the discovery that many developmental genes have multiple pseudogenes associated with them. Six known pseudogenes exist for Oct4, all of which exhibit very high sequence homology (three &gt;97%), and for this reason the generation of artefacts may have contributed to false identification of Oct4 in somatic cell populations. While ASC lack a molecular blueprint of transcription factors proposed to be involved with &apos;stemness&apos; as described for ES cells, it is not unreasonable to assume that similar gene patterns may exist. The focus of this work was to corroborate reports that Oct4 is involved in the regulation of ASC self-renewal and differentiation, using a combination of methodologies to rule out pseudogene interference. Haematopoietic stem cells (HSC) derived from human umbilical cord blood (UCB) and various differentiated cell lines underwent RT-PCR, product sequencing and transfection studies using an Oct4 promoter-driven reporter. In summary, only the positive control expressed Oct4, with all other cell types expressing a variety of Oct4 pseudogenes. Somatic cells were incapable of utilising an exogenous Oct4 promoter construct, leading to the conclusion that Oct4 does not appear involved in the multipotency of human HSC from UCB.</description>
        <link>http://www.jnrbm.com/content/9/1/2</link>
                <dc:creator>Zoe Redshaw</dc:creator>
                <dc:creator>Alastair Strain</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, 9:2</dc:source>
        <dc:date>2010-03-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-2</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2010-03-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/9/1/1">
        <title>Does computer use pose a hazard for future long-term sickness absence?</title>
        <description>The aim of the study was to investigate if weekly duration of computer use predicted sickness absence for more than two weeks at a later time.A cohort of 2146 frequent computer users filled in a questionnaire at baseline and was followed for one year with continuously recording of the duration of computer use and furthermore followed for 300 weeks in a central register of sickness absence for more than 2 weeks.147 participants of the 2,146 (6.9%) became first time sick listed in the follow-up period. Overall, mean weekly computer use did not turn out to be a risk factor for later sickness absence. The hazard ratio for sickness absence with weekly increase of one hour in computer use was 0.99 (95% CI: 0.99 to 1.00). Low satisfaction with work place arrangements and female gender both doubled the risk of sickness absence.We have earlier found that computer use did not predict persistent pain in the neck and upper limb, and it seems that computer use neither predicts future long-term sickness absence of all causes.</description>
        <link>http://www.jnrbm.com/content/9/1/1</link>
                <dc:creator>Johan Andersen</dc:creator>
                <dc:creator>Sigurd Mikkelsen</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2010, 9:1</dc:source>
        <dc:date>2010-03-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-9-1</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>9</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-03-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/12">
        <title>PALB2 variants in hereditary and unselected Finnish Prostate cancer cases </title>
        <description>Background:
PALB2 1592delT mutation is associated with increased breast cancer and suggestive prostate cancer (PRCA) risk in Finland. In this study we wanted to assess if any other PALB2 variants associate to increased PRCA risk and clinically describe patients with formerly found PALB2 1592delT mutation.
Methods:
Finnish families with two or more PRCA cases (n = 178) and unselected cases (n = 285) with complete clinical data were initially screened for variants in the coding region and splice sites of PALB2. Potentially interesting variants were verified in additional set of unselected cases (n = 463).
Results:
From our clinically defined sample set we identified total of six variants in PALB2. No novel variants among Finnish PRCA cases were found. Clinical characteristics of the variant carriers, including the previously described family carrying PALB2 1592delT, revealed a trend towards aggressive disease, which also applied to a few non-familial cases. Hypersensitivity to mitomycin C (MMC) of lymphoblasts from individuals from the family with 1592delT revealed haploinsufficiency among carriers with altered genotype.
Conclusions:
Though any of the detected PALB2 variants do not associate to PRCA in population level in Finland it cannot be ruled out that some of these variants contribute to cancer susceptibility at individual level.</description>
        <link>http://www.jnrbm.com/content/8/1/12</link>
                <dc:creator>Sanna Pakkanen</dc:creator>
                <dc:creator>Tiina Wahlfors</dc:creator>
                <dc:creator>Sanna Siltanen</dc:creator>
                <dc:creator>Mimmi Patrikainen</dc:creator>
                <dc:creator>Mika Matikainen</dc:creator>
                <dc:creator>Teuvo Tammela</dc:creator>
                <dc:creator>Johanna Schleutker</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, 8:12</dc:source>
        <dc:date>2009-12-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-12</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2009-12-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/11">
        <title>Human spongiosa mesenchymal stem cells fail to generate cardiomyocytes in vitro</title>
        <description>Background:
Human mesenchymal stem cells (hMSCs) are broadly discussed as a promising cell population amongst others for regenerative therapy of ischemic heart disease and its consequences. Although cardiac-specific differentiation of hMSCs was reported in several in vitro studies, these results were sometimes controversial and not reproducible.
Results:
In our study we have analyzed different published protocols of cardiac differentiation of hMSCs and their modifications, including the use of differentiation cocktails, different biomaterial scaffolds, co-culture techniques, and two- and three-dimensional cultures. We also studied whether 5&apos;-azacytidin and trichostatin A treatments in combination with the techniques mentioned above can increase the cardiomyogenic potential of hMSCs. We found that hMSCs failed to generate functionally active cardiomyocytes in vitro, although part of the cells demonstrated increased levels of cardiac-specific gene expression when treated with differentiation factors, chemical substances, or co-cultured with native cardiomyocytes.
Conclusion:
The failure of hMSCs to form cardiomyocytes makes doubtful the possibility of their use for mechanical reparation of the heart muscle.</description>
        <link>http://www.jnrbm.com/content/8/1/11</link>
                <dc:creator>Svetlana Mastitskaya</dc:creator>
                <dc:creator>Bernd Denecke</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, 8:11</dc:source>
        <dc:date>2009-11-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-11</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2009-11-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/10">
        <title>Lack of association between mutations of gene encoding mitochondrial D310 (displacement loop) mononucleotide repeat and oxidative stress in chronic dialysis patients in Taiwan</title>
        <description>Background:
Mitochondria (mt) are highly susceptible to reactive oxygen species (ROS). In this study, we investigated the association between a region within the displacement loop (D-loop) in mtDNA that is highly susceptible to ROS and oxidative stress markers in chronic dialysis patients. We enrolled 184 chronic dialysis patients and 213 age-matched healthy subjects for comparison. Blood levels of oxidative stress markers, such as thiobarbituric acid reactive substances (TBARS) and free thiol, and the mtDNA copy number were determined. A mononucleotide repeat sequence (CCCC...CCCTCCCCCC) between nucleotides 303 and 316-318 (D310) was identified in mtDNA.
Results:
Depending on alterations in the D310 mononucleotide repeat, subjects were categorized into 4 subgroups: 7-C, 8-C, 9 or 10-C, and T-to-C transition. Oxidative stress was higher in chronic dialysis patients, evidenced by higher levels of TBARS and mtDNA copy number, and a lower level of free thiol. The distribution of 7-C, 8-C, and 9-10C in dialysis and control subjects was as follows: 7-C (38% vs. 31.5%), 8-C (35.3% vs. 43.2%), and 9-10C (24.5% vs. 22.1%). Although there were significant differences in levels of TBARS, free thiol, and the mtDNA copy number in the D310 repeat subgroups (except T-to-C transition) between dialysis patients and control subjects, post hoc analyses within the same study cohort revealed no significant differences.
Conclusion:
Although oxidative stress was elevated in chronic dialysis patients and resulted in a compensatory increase in the mtDNA copy number, homopolymeric C repeats in the mtDNA region (D310), susceptible to ROS, were not associated with oxidative stress markers in these patients.</description>
        <link>http://www.jnrbm.com/content/8/1/10</link>
                <dc:creator>Jin-Bor Chen</dc:creator>
                <dc:creator>Tsu-Kung Lin</dc:creator>
                <dc:creator>Shang-Chih Liao</dc:creator>
                <dc:creator>Wen-Chin Lee</dc:creator>
                <dc:creator>Lung-Chih Lee</dc:creator>
                <dc:creator>Chia-Wei Liou</dc:creator>
                <dc:creator>Pei-Wen Wang</dc:creator>
                <dc:creator>Mao-Meng Tiao</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, 8:10</dc:source>
        <dc:date>2009-11-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-10</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2009-11-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/9">
        <title>Expression of estrogen and progesterone receptors in vestibular schwannomas and their clinical significance</title>
        <description>ObjectiveThe objective was to determine the expression of estrogen and progesterone receptors in vestibular schwannomas as well as to determine predictive factors for estrogen and progesterone receptor positivity.Materials and methodsThe study included 100 cases of vestibular schwannomas operated from January 2006 to June 2009. The clinical details were noted from the medical case files. Formaldehyde-fixed parafiin-embedded archival vestibular schwannomas specimens were used for the immunohistochemical assessment of estrogen and progesterone receptors.
Results:
Neither estrogen nor progesterone receptors could be detected in any of our cases by means of well known immunohistochemical method using well documented monoclonal antibodies. In the control specimens, a strongly positive reaction could be seen.
Conclusion:
No estrogen and progesterone receptor could be found in any of our 100 cases of vestibular schwannomas. Hence our study does not support a causative role of estrogen and progesterone in the growth of vestibular schwannoma as well as hormonal manipulation in the treatment of this tumor.</description>
        <link>http://www.jnrbm.com/content/8/1/9</link>
                <dc:creator>Sushila Jaiswal</dc:creator>
                <dc:creator>Vinita Agrawal</dc:creator>
                <dc:creator>Awadhesh Jaiswal</dc:creator>
                <dc:creator>Rakesh Pandey</dc:creator>
                <dc:creator>Ashok Mahapatra</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, 8:9</dc:source>
        <dc:date>2009-11-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-9</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2009-11-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.jnrbm.com/content/8/1/8">
        <title>Refractoriness of hepatitis C virus internal ribosome entry site to processing by Dicer in vivo</title>
        <description>Background:
Hepatitis C virus (HCV) is a positive-strand RNA virus harboring a highly structured internal ribosome entry site (IRES) in the 5&apos; nontranslated region of its genome. Important for initiating translation of viral RNAs into proteins, the HCV IRES is composed of RNA structures reminiscent of microRNA precursors that may be targeted by the host RNA silencing machinery.
Results:
We report that HCV IRES can be recognized and processed into small RNAs by the human ribonuclease Dicer in vitro. Furthermore, we identify domains II, III and VI of HCV IRES as potential substrates for Dicer in vitro. However, maintenance of the functional integrity of the HCV IRES in response to Dicer overexpression suggests that the structure of the HCV IRES abrogates its processing by Dicer in vivo.
Conclusion:
Our results suggest that the HCV IRES may have evolved to adopt a structure or a cellular context that is refractory to Dicer processing, which may contribute to viral escape of the host RNA silencing machinery.</description>
        <link>http://www.jnrbm.com/content/8/1/8</link>
                <dc:creator>Dominique Ouellet</dc:creator>
                <dc:creator>Isabelle Plante</dc:creator>
                <dc:creator>Vincent Boissonneault</dc:creator>
                <dc:creator>Cherifa Ayari</dc:creator>
                <dc:creator>Patrick Provost</dc:creator>
                <dc:source>Journal of Negative Results in BioMedicine 2009, 8:8</dc:source>
        <dc:date>2009-08-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1477-5751-8-8</dc:identifier>
        <prism:publicationName>Journal of Negative Results in BioMedicine</prism:publicationName>
        <prism:issn>1477-5751</prism:issn>
        <prism:volume>8</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2009-08-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
